Sulfamerazine
Based on 4 publication(s) in Google Scholar
Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.82%
- CAS No.: 127-79-7
- 화학식: C11H12N4O2S
- 분자량:264.30
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
CNS-Penetrant Compound Library
HY-L028
-
Peptidomimetic Library
HY-L033
-
Drug Repurposing Compound Library
HY-L035
-
Antibacterial Compound Library
HY-L049
-
Anti-COVID-19 Compound Library
HY-L052
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Sulfamerazine
MoreAll Antibiotic Isoforms
MoreAll α-synuclein Isoforms
More
Biological Activity
Antibacterial
Sulfamerazine (5-25 μM) reproducibly inhibits α-Syn fibrillation[1].
Sulfamerazine (0.31 μM; 24 h) reduces the accumulation of α-Syn aggregates in neuronal SH-SY5Y cells[1].
Sulfamerazine (25-200 μM; 24-48 h) is nontoxic to human neuroblastoma SH-SY5Y cells at concentrations up to 100 μM over 24-48 h, with reduced viability observed only at 200 μM[1].
Sulfamerazine (25-100 μM) exhibits a significant reduction in α-Syn aggregation and associated toxicity in Caenorhabditis elegans model of PD[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human neuroblastoma SH-SY5Y cells
-
Concentration:25 μM; 50 μM; 100 μM; 200 μM
-
Incubation Time:24 h; 48 h
-
Result:Showed no significant toxicity up to 100 μM after 24 h and 48 h.
Decreased cell viability to ~70% at 200 μM after 24 h and ~40% at 200 μM after 48 h.
Chemical Information
-
CAS No. 127-79-7
-
Appearance Solid
-
분자량 264.30
-
화학식 C11H12N4O2S
-
Color White to off-white
-
SMILES
O=S(C1=CC=C(N)C=C1)(NC2=NC=CC(C)=N2)=O
-
Synonyms
RP2632
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Drug Deliv Transl Res
Leveraging quantum chemical properties in transfer learning for predicting blood-brain barrier permeability of drugs. [Abstract]2025 Oct 29. PMID: 41160380 -
용액&용해도
DMSO : ≥ 100 mg/mL (378.36 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (287 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7836 mL | 18.9179 mL | 37.8358 mL | 94.5895 mL |
| 5 mM | 0.7567 mL | 3.7836 mL | 7.5672 mL | 18.9179 mL | |
| 10 mM | 0.3784 mL | 1.8918 mL | 3.7836 mL | 9.4589 mL | |
| 15 mM | 0.2522 mL | 1.2612 mL | 2.5224 mL | 6.3060 mL | |
| 20 mM | 0.1892 mL | 0.9459 mL | 1.8918 mL | 4.7295 mL | |
| 25 mM | 0.1513 mL | 0.7567 mL | 1.5134 mL | 3.7836 mL | |
| 30 mM | 0.1261 mL | 0.6306 mL | 1.2612 mL | 3.1530 mL | |
| 40 mM | 0.0946 mL | 0.4729 mL | 0.9459 mL | 2.3647 mL | |
| 50 mM | 0.0757 mL | 0.3784 mL | 0.7567 mL | 1.8918 mL | |
| 60 mM | 0.0631 mL | 0.3153 mL | 0.6306 mL | 1.5765 mL | |
| 80 mM | 0.0473 mL | 0.2365 mL | 0.4729 mL | 1.1824 mL | |
| 100 mM | 0.0378 mL | 0.1892 mL | 0.3784 mL | 0.9459 mL |
Sulfamerazine Related Classifications
HY-B0512 Related Classifications
Powered by Bioz
- Sulfamerazine
- 127-79-7
- RP2632
- RP 2632
- RP-2632
- Antibiotic
- Bacterial
- α-synuclein
- Parkinson’s disease
- meningococcal meningitis
- yeast Ure2 protein
- transgenic C. elegans
- pneumococcal infections
- gonococcal infections
- beta-hemolytic streptococcus infections
- urinary tract infections
- human neuroblastoma SH-SY5Y cells
- Inhibitor
- inhibitor
- inhibit